ClinicalTrials.gg
Active, not recruitingNCT05652218REINVENTUpdated Nov 4, 2026

REsynchronization Comparison In LBBB and Normal or Mildly Reduced VENTricular Function With CRT (REINVENT-CRT)

An interventional study of LB-CRT and BIV-CRT in Left Ventricular Ejection Fraction, Heart Failure (HF) and Left Bundle-Branch Block, sponsored by Inova Health Care Services. Active, not recruiting at 2 sites in United States. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Inova Health Care Services · Not applicable, Interventional, and Other

Updated Nov 4, 2026Study completion movedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
21
Allocation
Randomized
Sex
All
01

Study summary

Primary Objective - To determine if implantation of a permanent CRT pacing device (with LB-CRT, or conventional BiV-CRT with a coronary sinus LV lead) can improve electromechanical function, HF symptoms, and natriuretic peptide levels among patients with symptomatic HF, LVEF > 35%, and LBBB.

Read the detailed description

This pilot study will be a multicenter randomized controlled trial involving 20 medically stable outpatients with heart failure (HF), preserved or mildly reduced LVEF (>35%), and LBBB. Patients will undergo implantation of a Medtronic Percepta CRT-P with an atrial lead, left bundle branch area pacing (LBBap) lead, and a LV lead. They will then be randomly allocated in a 1:1 fashion to usual care plus LB-CRT (DDD 60-130, LV lead turned off) (active intervention #1) or usual care plus BIV-CRT (DDD 60- 130, LV lead turned on) (active intervention #2).

02

Conditions studied

  • Left Ventricular Ejection Fraction
  • Heart Failure (HF)
  • Left Bundle-Branch Block
03

In context

Heart Failure

6,331 studies on the registry are indexed under Heart Failure; 1,396 are open to participants now.

This study's enrollment of 21 is below the median of 76 across 4,049 interventional studies indexed under Heart Failure.

Browse Heart Failure studies →

Lead sponsor

Inova Health Care Services is the lead sponsor of 86 studies on the registry; 20 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 8 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to understand and the willingness to sign a written form and HIPAA Authorization.
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female aged ≥18 years
  • Strict LBBB defined as QRS duration ≥130ms in women and ≥140ms in men, a QS or rS complex in V1 and V2, as well as notching or QRS slurring in mid-QRS in ≥2 contiguous leads.
  • II/III, ambulatory NYHA IV, or NYHA I HF with any prior history of HF symptom decompensation requiring hospitalization, ED visit, or outpatient visit for care with IV diuretic
  • >35% by clinically obtained echocardiogram overread by the study core-lab
  • Demonstration of adequate echocardiographic images to allow for assessment of endpoints
  • On a stable guideline directed HF medical regimen
  • For females of : use of a highly effective for at least 1 month prior to screening and agreement to use such a method during study participation
  • Ability to understand and the willingness to sign a written informed consent form and HIPAA Authorization.

Exclusion criteria

Exclusion Criteria:

  • Patients with anticipated addition or titration of HF medical therapies (ACE/ARB/ARNI, beta blocker, MRA, SGLT2 inhibitor) during the duration of the study
  • Treatment with another drug or other intervention within 3 months
  • Current unrevascularized coronary artery disease, unstable angina, acute MI, CABG, or PCI within the past 3 months
  • Significant non-functional mitral or aortic valvular disease (severe stenosis or regurgitation)
  • Significant structural heart [including hypertrophic cardiomyopathy (septal thickness ≥15 mm) or infiltrative cardiomyopathy (eg. amyloid)]
  • Current moderate to severe pulmonary hypertension (right ventricular systolic pressure of ≥40 mmHg)
  • Oxygen dependent chronic lung disease
  • Prolonged episodes of AF (>3 days or an AF burden >10%) within the preceding 3 months
  • Presence of cardiac pacemaker or implantable cardioverter defibrillator
  • Prior mechanical tricuspid valve replacement
  • Pregnancy or lactation due to concerns about the effect of radiation from the pacemaker implantation procedure on the fetus
  • Known allergic reactions to components of the pacemaker or leads
  • Febrile illness within 3 days of trial enrollment
  • Parents/guardians or participants who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.
  • Control Participant Exclusion Criteria: same
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Care provider)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Sequence 1

    LB-CRT - Left Bundle Cardiac Resynchronization Therapy, Participants will spend 3 months in this group

    Device: LB-CRT · Device: BIV-CRT

  • Experimental
    Sequence 2

    BiV-CRT - Biventricular Pacing Cardiac Resynchronization Therapy. Participants will spend 3 months in this group

    Device: LB-CRT · Device: BIV-CRT

Interventions

  • DeviceLB-CRT

    LB-CRT (DDD 60-130, LV lead turned off) (active intervention #1)

  • DeviceBIV-CRT

    BIV-CRT (DDD 60- 130, LV lead turned on) (active intervention #2).

06

What researchers measure

Primary outcomes

  1. Change in myocardial performance index (MPI) as compared to Baseline

    Myocardial performance index (MPI), a global measure of cardiac performance is defined using tissue Doppler imaging.

    Time frame: Baseline and 3 month treatment period after each pacing mode

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Study completion
Sep 30, 2026→Mar 30, 2027
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Study completion Sep 30, 2026→Mar 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05652218
Lead sponsor
Inova Health Care Services
Collaborators
Medtronic
Responsible party
Brett Atwater, MD (Director of Electrophysiology and Electrophysiology Research, Inova Health Care Services) — Principal investigator
First posted
Dec 15, 2022
Start date
Feb 26, 2023
Primary completion
Feb 28, 2026
Completion
Mar 30, 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Brett Atwater, MD
principal investigator · Inova Health Care Services

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion